Cargando…
Comparison of Benzbromarone and Allopurinol on Primary Prevention of the First Gout Flare in Asymptomatic Hyperuricemia
Objectives. Whether uric acid-lowering agent use in asymptomatic hyperuricemia can reduce the development of the first gout flare remains unsettled. The goal of the present research was to test the efficacy of benzbromarone and allopurinol on primary prevention of the first gout flare in persons wit...
Autores principales: | Lai, Shih-Wei, Liao, Kuan-Fu, Kuo, Yu-Hung, Liu, Chiu-Shong, Hwang, Bing-Fang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9144668/ https://www.ncbi.nlm.nih.gov/pubmed/35629121 http://dx.doi.org/10.3390/jpm12050697 |
Ejemplares similares
-
A Head-To-Head Comparison of Benzbromarone and Allopurinol on the Risk of Type 2 Diabetes Mellitus in People With Asymptomatic Hyperuricemia
por: Lai, Shih-Wei, et al.
Publicado: (2021) -
The risk of ischemic cerebrovascular disease associated with benzbromarone use in gout people: A retrospective cohort study in Taiwan
por: Lai, Shih-Wei, et al.
Publicado: (2023) -
Cardiovascular risk associated with allopurinol vs. benzbromarone in patients with gout
por: Kang, Eun Ha, et al.
Publicado: (2021) -
Cardiovascular risk associated with allopurinol or benzbromarone
treatment in patients with gout
por: Eun, Yeonghee, et al.
Publicado: (2022) -
Sex differences in response to allopurinol and benzbromarone in gout: a retrospective cohort study
por: Veenstra, Frouwke, et al.
Publicado: (2021)